Atlanta 12/20/2012 2:36:09 AM
Lightlake Therapeutics Inc (Stock Symbol: OTN: LLTP) is now on LinkMyStock.com
Lightlake Therapeutics Inc has joined LinkMyStock.com. Now Stock Brokers, Brokerage Firms and Investors/Shareholders from around the world who follow Lightlake Therapeutics Inc can link directly to Lightlake Therapeutics Inc Link My Stock Hub. Brokers and Brokerage Firms that link to Lightlake Therapeutics Inc typically are familiar with the company and can facilitate transactions in Lightlake Therapeutics Inc security. Investors linking to Lightlake Therapeutics Inc usually are either existing shareholders looking to stay informed when Lightlake Therapeutics Inc posts new information or people that are simply interested in Lightlake Therapeutics Inc that are not yet or may never become shareholders.
LinkMyStock is a premier financial networking platform designed specifically for public companies, brokerage firms, brokers and investors. LinkMyStock.com provides a network that consists of brokers, brokerage firms and investors that can link directly to the companies that they follow. With brokers from around the world having the ability to select companies to link to that are members of Link My Stock this provides investors with the ability to locate brokers and contact them to find out more information about a company they are interested in learning more about.
LinkMyStock.com provides every member with their own hub where they post content. Content sections include; press releases, blogs, pictures, videos, Right Now status updates, events, jobs and more in order to attract more visitors and increase the number of search results along with improving indexing.
To link to the Lightlake Therapeutics Inc.'s Link My Stock Hub sign into your Link My Stock Hub or Join Link My Stock today.
About Lightlake Therapeutics Inc
We are a London-based biopharmaceutical company using our expertise of opioid antagonists to develop modern addiction treatments. Our current focus is on completing the clinical trials of an opioid antagonist-based nasal spray for the treatment of Binge Eating Disorder, which is the most common eating disorder in the US today. For our future endeavors, we recently acquired patents that will allow us to widen our product pipeline to address patients with addictions to opioid painkillers, methadone, cocaine and amphetamine.
